Patent · US Active

Solid pharmaceutical dosage form

US8025899B2 · kind B2 · utility

10Cited by

101References

14Claims

0Family size

Assignee

Abbott Laboratories · US

Inventors

Gunther Berndl · Herxheim, DE
Joerg Rosenberg · Ellerstadt, DE
Bernd Liepold · Dossenheim, DE
Joerg Breitenbach · Mannheim, DE
Ulrich Reinhold · Heidelberg, DE
Laman Alani · Morristown, US
Soumojeet Ghosh · Gurnee, US

Key dates

Filing date	Aug 25, 2004
Grant date	Sep 27, 2011
Priority date	—
Expiry date	Sep 26, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/1635
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.